SkyShowtime Announces Official Launch Date and Content Line-Up
14.9.2022 17:56:00 EEST | Business Wire | Press release
New streaming service SkyShowtime today announced that it will officially launch on 20 September 2022, bringing its premium offering of exclusive and iconic entertainment to millions of homes across Europe for the first time.
A joint venture of Comcast (NASDAQ: CMCSA) —parent company of NBCUniversal and Sky— and Paramount Global (NASDAQ: PARA, PARAA), SkyShowtime will launch in Denmark, Finland, Norway and Sweden on 20 September, before expanding into the Netherlands later this year in Q4. SkyShowtime will continue its roll out across Spain, Portugal, Andorra, and Central & Eastern Europe (CEE) over the coming months and through Q1 2023. CEE markets include Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Kosovo, Montenegro, North Macedonia, Poland, Romania, Serbia, Slovakia and Slovenia. Specific launch dates and pricing in these markets will be announced in the coming months.
SkyShowtime brings together the best entertainment from the world’s greatest studios and storytellers. Featuring thousands of hours of quality entertainment for the whole family, the service will be home to a wide selection of the world’s most highly anticipated series and movies.
It will feature the exclusive television premieres of first-run theatrical films from Paramount Pictures and Universal Pictures, Hollywood’s two oldest studios and which together account for nearly 50% of Hollywood box office.
SkyShowtime will be the home to a selection of new blockbuster films following their theatrical and home entertainment release, including Top Gun: Maverick, Jurassic World Dominion, Minions: The Rise of Gru, The Northman, Sing 2, Sonic the Hedgehog 2, The Lost City, Downton Abbey: A New Era, Nope, Belfast, Ambulance and The Bad Guys.
In addition, SkyShowtime features new premium scripted series, kids and family content and a selection of iconic library titles and box sets from Universal Pictures, Paramount Pictures, Nickelodeon, DreamWorks Animation, Paramount+, SHOWTIME®, Sky Studios and Peacock - all streaming in one place. SkyShowtime will also feature local original programming, documentaries and specials from its markets.
In the Nordics, as part of the partnership with Paramount, SkyShowtime will replace Paramount+, allowing existing and future customers to watch current Paramount+ favourites such as Halo, Yellowstone, The Offer and Star Trek: Strange New Worlds, as well as SHOWTIME® originals Yellowjackets, Dexter: New Blood, Super Pumped: The Battle for Uber, and The First Lady. And for the first time, subscribers will gain access to even more new and exclusive premium series and movies spanning the best of Universal Pictures, Sky Originals and NBCUniversal.
From launch, customers can watch series premieres of highly anticipated SHOWTIME® drama American Gigolo, Sky Originals The Rising, The Fear Index, and The Midwich Cuckoos, as well as Law & Order Season 21 from Peacock. Over the coming months, additional series premieres will include Yellowstone Season 5, Pitch Perfect: Bumper in Berlin, Vampire Academy and SHOWTIME® series Yellowjackets Season 2 and Let The Right One In.
SkyShowtime CEO Monty Sarhan said: “It’s time… for SkyShowtime, — the next great streaming service for Europe. Just months after receiving full regulatory approval, SkyShowtime will officially launch on 20 September 2022. We’re excited for our customers to have exclusive access to the latest series and movie premieres from our iconic and world-renowned studios. We look forward to sharing further details about launch dates for our other markets and bringing SkyShowtime to even more people across Europe.”
SkyShowtime Regional General Manager for Northern Europe Henriette Skov commented: “We’re thrilled to launch SkyShowtime across the Nordics and look forward to offering our customers the very best selection of global series and movies all in one place.”
The service will be available direct-to-consumer via the SkyShowtime app across Apple iOS, tvOS, Android devices, and through the website: www.skyshowtime.com. SkyShowtime’s monthly price will be €6,99 in Finland, SEK 79 in Sweden, NOK 79 in Norway, and DKK 69 in Denmark.
SkyShowtime will also be available through the following distribution partners across its Nordic markets: Allente, RiksTV, Ruutu, Sappa, Strim, Telenor, Tele2, Telia, Telmore and YouSee from Nuuday Group, and TV 2 Play.
Powered by the Peacock platform, SkyShowtime was created specifically for Europe and is dedicated to these markets. With regional offices across its territories, SkyShowtime’s customer-centric focus and local market presence informs its approach to partnerships, content, and marketing. Once launched across more than 20 countries, SkyShowtime’s apps and content will be available in 18 different languages.
The content line up detailed in this press release is Nordic-specific and may vary per market.
For the trailer, please access here: https://youtu.be/ujzpT7FTeeY
For more details, please visit:
Website: www.skyshowtime.com
Newsroom: corporate.skyshowtime.com
LinkedIn: www.linkedin.com/company/skyshowtime
For further information, please email skyshowtimeenquiries@mcsaatchi.com
About SkyShowtime
SkyShowtime is a new streaming service that will launch in the Nordics on 20th September, this year.
A joint venture of Comcast Corporation (NASDAQ: CMCSA) and Paramount Global (NASDAQ: PARA, PARAA), SkyShowtime brings together the combined resources of both companies, direct-to-consumer experience, and the very best entertainment, movies, and original series from the iconic brands of Universal Pictures, DreamWorks, Sky Studios, Peacock, Paramount +, SHOWTIME®, Paramount Pictures and Nickelodeon.
SkyShowtime will be available in more than 20 European markets encompassing 90 million homes. It will be offered in Albania, Andorra, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Finland, Hungary, Kosovo, Montenegro, Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, and Sweden.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220905005022/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom